title: Does the Prostate Health Index Depend on Tumor Volume?-A Study on 196 Patients after Radical Prostatectomy.
abstract: The Prostate Health Index (PHI) has been used increasingly in the context of prostate cancer (PCa) diagnostics since 2010. Previous studies have shown an association between PHI and a tumor volume of >0.5 cm³. The aim of this study was to investigate the correlation between PHI and tumor volume as well as the Gleason score. A total of 196 selected patients with prostate cancer treated with radical prostatectomy at our institution were included in our study. The tumor volume was calculated and preoperative serum parameters total prostate-specific antigen (tPSA), free PSA (fPSA), [-2]proPSA, and PHI were evaluated. The association between the pathological findings such as Gleason score, pathological T-stage (pT stage), and tumor volume were evaluated. We further used logistic regression and Cox proportional hazard regression analyses for assessing the association between tumor volume and PHI and for predicting biochemical recurrence. With an area under the curve (AUC) of 0.79, PHI is the most accurate predictor of a tumor volumes >0.5 cm³. Moreover, PHI correlates significantly with the tumor volume (r= 0.588), which is significantly different (p= 0.008) from the correlation of the Gleason score with tumor volume (r= 0.385). PHI correlates more strongly with the tumor volume than does the Gleason score. Using PHI improves the prediction of larger tumor volume and subsequently clinically significant cancer.
authors.affiliation: Department of Urology, Charité University Hospital, 10098 Berlin, Germany. frank.friedersdorff@charite.de.
authors.forename: Frank
authors.initials: F
authors.lastname: Friedersdorff
authors.affiliation: Department of Urology, Charité University Hospital, 10098 Berlin, Germany. grossbritt@yahoo.de.
authors.forename: Britt
authors.initials: B
authors.lastname: Groß
authors.affiliation: Department of Urology, Charité University Hospital, 10098 Berlin, Germany. andres.maxeiner@charite.de.
authors.forename: Andreas
authors.initials: A
authors.lastname: Maxeiner
authors.affiliation: Department of Urology, Charité University Hospital, 10098 Berlin, Germany. klaus.jung@charite.de.|Berlin Institute for Urologic Research, 10115 Berlin, Germany. klaus.jung@charite.de.
authors.forename: Klaus
authors.initials: K
authors.lastname: Jung
authors.affiliation: Department of Urology, Charité University Hospital, 10098 Berlin, Germany. kurt.miller@charite.de.
authors.forename: Kurt
authors.initials: K
authors.lastname: Miller
authors.affiliation: Department of Urology, Charité University Hospital, 10098 Berlin, Germany. carsten.stephan@charite.de.|Berlin Institute for Urologic Research, 10115 Berlin, Germany. carsten.stephan@charite.de.
authors.forename: Carsten
authors.initials: C
authors.lastname: Stephan
authors.affiliation: Department of Urology, Charité University Hospital, 10098 Berlin, Germany. Jonas.busch@charite.de.
authors.forename: Jonas
authors.initials: J
authors.lastname: Busch
authors.affiliation: Department of Pathology, Charité University Hospital, 10098 Berlin, Germany. ergin.kilic@charite.de.
authors.forename: Ergin
authors.initials: E
authors.lastname: Kilic
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D001706:Biopsy; D015331:Cohort Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000601:surgery; D012372:ROC Curve; D012008:Recurrence; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
keywords: Prostate Health Index; prostate cancer; tumor volume